# US 2025/0144233 A1 · Novel gene delivery agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144233 A1
- Document ID: US20250144233A1
- Status: Published application
- Kind: A1
- Application number: 18/932,511
- Filed: 2024-10-30
- Published: 2025-05-08
- Earliest claimed: 2023-10-31
- Assignees: TIBA Biotech LLC
- Applicants: Tiba Biotech LLC.
- Inventors: Poulami Talukder; Maria Varghese; Heliang Song; Nathan Ivanowsky
- Web page: https://patentgrep.com/patent/US20250144233A1

## CPC

- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- C07C 69/34: Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- C07C 233/36: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 323/12: the carbon skeleton being acyclic and saturated
- C07C 323/60: with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 207/46: with hetero atoms directly attached to the ring nitrogen atom
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07F 9/10: Phosphatides, e.g. lecithin
- C07F 9/650952: {having the nitrogen atoms in the positions 1 and 4}
- C07F 9/6518: Five-membered rings
- C07H 15/04: attached to an oxygen atom of the saccharide radical
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Nanoparticle compositions for delivery of nucleic acids to subjects including aminoalkyl branched lipid-like molecules as carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the nanoparticle containing are described. Also provided are methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects.

## Claims

### Claim 1

A compound of Formula I:
in which
YA is H, C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl;
ZA is H, halo, hydroxyl, C1-C30 amino, C1-C30 amido, C1-C30 carbonyl, C1-C30 carboxylate, sugar, diazolyl, triazolyl, phosphate, ethylene glycol, or C4-C30 polyethylene glycol;
ZB is H or
each of LC or LD is CH2 or O;
each of ZC and ZD, independently, is C1-C30 alkyl, C2-C30 alkenyl, or C2-C30 alkynyl;
LK1 is C3-C8 alkylene, C3-C8 alkenylene, C3-C8 alkynylene, or alkylene-heterocycloalkylene-alkylene;
each of LK2, LK3, and LK4, independently, is a bond, C1-C8 alkylene, C2-C8 alkenylene, C2-C8 alkynylene, or alkylene-heterocycloalkylene-alkylene; and
wherein the compound has 20 to 200 carbon atoms.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each of alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkylene-heterocycloalkylene-alkylene, amino, amido, carbonyl, carboxylate is unsubstituted or substituted with one or more of halo, hydroxyl, C1-C6 amino, C2-C6 carbamate, C2-C20 carboxylate, C2-C20 carbonyl, aryl, C1-C10 phosphate, ethylene glycol, C4-C30 polyethylene glycol, C1-C30 disulfanyl, diazolyl, triazolyl, or sugar; and each of diazolyl, triazolyl, phosphate and sugar is unsubstituted or substituted with halo, hydroxyl, alkyl, alkenyl, alkynyl, C1-C6 amino, C2-C6 carbamate, C2-C20 carboxylate, C2-C20 carbonyl, aryl, C1-C10 phosphate, ethylene glycol, C4-C30 polyethylene glycol, C1-C30 disulfanyl, diazolyl, triazolyl, nucleobase or sugar.

### Claim 3 (depends on 2)

The compound of claim 2, wherein disulfanyl is unsubstituted or substituted with one or more of halo, hydroxyl, aryl, and C1-C20 carboxylate; each of diazolyl and triazolyl is unsubstituted or substituted with one or more of halo, C1-C20 alkyl, C2-C20 alkenyl, and C2-C20 alkynyl; and the compound has 40 to 100 carbon atoms and at least a moiety selected from disulfanyl, diazolyl, triazolyl, phosphate, ethylene glycol, polyethylene glycol, and sugar.

### Claim 4 (depends on 1)

The compound of claim 1, wherein YA is H or C1-C4 alkyl, and alkyl is unsubstituted or substituted with one or more groups selected from hydroxyl, halo, sugar, C1-C6 amino, C1-C6 carbamate, C4-C30 polyethylene glycol, ethylene glycol, phosphate, nucleobase, imidazole, morpholine, pyrrolidine, piperidine and piperazine, acetyl, methylsulfonyl, methylformamido, dimethylformamido, methylthioforamido, dimethylthioformamido, (E)-N′-cyano-N-methylformimidamido, (E)-N′-cyano-N,N-dimethylformimidamideo (E)-N′-nitroformimidamido, (E)-N,N-dimethyl-N′-nitroformimidamido, (E)-N′-methoxyformimidamido, (E)-N′-sulfamoylformimidamido, thiazoyl, 2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl, 2-(dimethylamino)-3,4-dioxocyclobut-1-en-1-yl, 2-(methylcarbamoyl)acetyl, and malonamido.

### Claim 5 (depends on 4)

The compound of claim 4, wherein YA is H, —CH3, —C2H5, —C3H7, —C2H4OH, —C3H6OH, —C2H4N(CH3)2, —C3H6N(CH3)2, —C2H4O(CO)NHCH3, C3H6OC14H19O9, —C3H6O(CO)NHCH3, or —C3H6OP(O)(OC2H5)2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein LK1 is —(CH2)3—, —(CH2)4—, or
in which each of 1, m, n independently is 0 to 20; Y is H, —OH, —OMe, —NMe2,
heterocycloalkyl, aryl, or heteroaryl; preferably, LK1 is —(CH2)3—, —(CH2)4—, or

### Claim 7 (depends on 1)

The compound of claim 1, wherein each of LK2, LK3, and LK4, independently, is —(CH2)2— or —(CH2)3—.

### Claim 8 (depends on 1)

The compound of claim 1, wherein each of LC and LD is O.

### Claim 9 (depends on 1)

The compound of claim 1, wherein, ZA is C2-C20 amino, C2-C20 amido, C2-C20 carboxylate, diazolyl, triazolyl, or disulfanyl, each of amino, amido, carboxylate, or disulfanyl is unsubstituted or substituted with one or more groups selected from halo, hydroxyl, disulfanyl, carboxylate, sugar, phosphate, ethylene glycol, and C4-C30 polyethylene glycol; and each of diazolyl and triazolyl is unsubstituted or substituted with one or more groups selected from halo, hydroxyl, alkyl, alkenyl, alkynyl, disulfanyl, carboxylate, sugar, phosphate, ethylene glycol, and C4-C30 polyethylene glycol, preferably, ZA contains one or more groups selected from hydroxyl, sugar, phosphate, ethylene glycol, and C4-C10 polyethylene glycol.

### Claim 10 (depends on 1)

The compound of claim 1, wherein ZA is C2-C20 amino substituted with one or more of —C(O)—O-ZA2-XA-XA-ZA3, —C(O)—O-ZA2-(XA-XA-ZA3)2, —C(O)—O-ZA2-(XA-XA-ZA3)3, —C(O)—O-ZA2-diazolyl-ZA4, —C(O)—O-ZA2-triazolyl-ZA4, —C(O)—O-ZA4, in which XA is CH2 or S; ZA2 is C4-C10 alkylene, C4-C10 alkenylene, or C4-C10 alkynylene; and each of ZA3 and ZA4, independently, is C1-C30 alkyl, N(CH3)2, or NHCH3.

### Claim 11 (depends on 1)

The compound of claim 1, wherein ZB is H, ZB1-C(O)—O-ZB2-XB—XB-ZB3, ZB1-C(O)—O-ZB2-(XB—XB-ZB3)2, ZB1-C(O)—O-ZB2-(XB—XB-ZB3)3, -ZB1-C(O)—O-ZB2-diazolyl-ZB4, -ZB1-C(O)—O-ZB2-triazolyl-ZB4, -ZB1-C(O)—O-ZB4, in which XB is CH2 or S; ZB1 is C1-C4 alkylene; ZB2 is C4-C10 alkylene, C4-C10 alkenylene, or C4-C10 alkynylene; and each of ZB3 and ZB4, independently, is C1-C30 alkyl, N(CH3)2, or NHCH3.

### Claim 12 (depends on 11)

The compound of claim 11, wherein ZB is H, —(CH2)nb1—C(O)—O—(CH2)nb2—XB—XB—(CH2)nb3, —(CH2)nb1—C(O)—O—(CH2)nb2-diazolyl-Z, —(CH2)nb1—C(O)—O—(CH2)nb2-triazolyl-Z, —(CH2)nb1—C(O)—O-Z, in which XB is CH2 or S; Y is H, —CH3, —C2H5, —C3H7, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2N(CH3)2, —CH2CH2CH2N(CH3)2, —CH2CH2OC(O)—NHCH3, —CH2CH2CH2OC(O)—NHCH3; Z is C1-C30 alkyl, N(CH3)2, or NHCH3; nb1 is 1-4; nb2 is 4-10; and nb3 is 1-20.

### Claim 13 (depends on 1)

The compound of claim 1, wherein ZC is ZC2-XC—XC-ZC3, ZC2-(XC—XC-ZC3)2, ZC2-(XC—XC-ZC3)3, ZC1-C(O)—O-ZC2-XC—XC-ZC3, -ZC2-diazolyl-ZC4, -ZC2-triazolyl-ZC4, ZC4, in which XC is CH2 or S; ZC1 is C1-C4 alkylene; ZC2 is C4-C10 alkylene, C4-C10 alkenylene, or C4-C10 alkynylene; and each of ZC3 and ZC4, independently, is C1-C30 alkyl, N(CH3)2, or NHCH3.

### Claim 14 (depends on 13)

The compound of claim 13, wherein ZC is Z, —(CH2)nc2—XC—XC—(CH2)nc3, —(CH2)nc1—C(O)—O—(CH2)nc2-diazolyl-Z, or —(CH2)nc2-triazolyl-Z, in which XC is CH2 or S; Z is C1-C30 alkyl, N(CH3)2, or NHCH3; nc1 is 1-4, nc2 is 4-10, and nc3 is 1-20.

### Claim 15 (depends on 11)

The compound of claim 11, wherein ZA contains one or more groups selected from hydroxyl, sugar, phosphate, ethylene glycol, and C4-C10 polyethylene glycol; each of LK3 and LK4 is —(CH2)2—; ZB is —(CH2)2—C(O)—O—(CH2)nb2—XB—XB-ZB3; ZC is —(CH2)nc2—XC—XC-ZC3; each of XC and XB is S; each of nb2 and nc2, independently, is 5-8, preferably 6; and each of ZB3 and ZC3, independently, is C6-C12 alkyl.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, or 1i:
in which X is CH2 or S; Y is H, X is CH2 or S; Y is H, CH3, C2H5, C3H7, CH2CH2OH, CH2CH2CH2OH, CH2CH2N(CH3)2, CH2CH2CH2N(CH3)2, CH2CH2OC(O)NHCH3, CH2CH2CH2OC(O)NHCH3; Z is C1-C30 alkyl, N(CH3)2, or NHCH3; R is OH, OCH3, CH3, N(CH3)2, CF3, sugar, phosphate, ethylene glycol, or C4-C30 polyethylene glycol; and n is 0 to 20.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is one of Compounds 3, 5, 6, 8, 9, 13, 15, 18, 20-22, and 25-44.

### Claim 18 (depends on 1)

A nanoparticle composition comprising a compound of claim 1, and a therapeutic or immunogenic nucleic acid agent fully or partially encapsulated therein.

### Claim 19 (depends on 18)

The nanoparticle composition of claim 18, wherein the therapeutic or immunogenic nucleic acid agent is selected from the group consisting of a polynucleotide, oligonucleotide, DNA, cDNA, RNA, repRNA, siRNA, miRNA, sgRNA, and mRNA.

### Claim 20 (depends on 18)

The nanoparticle composition of claim 18, wherein the therapeutic or immunogenic nucleic acid agent encodes one or more antigens selected from the group consisting of infectious disease, pathogen, cancer, autoimmunity disease and allergenic disease.

### Claim 21 (depends on 18)

The nanoparticle composition of claim 18, wherein the therapeutic or immunogenic nucleic acid agent comprises an RNA or DNA capable of silencing, inhibiting or modifying the activity of a gene.

### Claim 22 (depends on 18)

The nanoparticle composition of claim 18 further comprising a PEG-lipid.

### Claim 23 (depends on 18)

The nanoparticle composition of claim 18, further comprising a PEG-lipid, preferable where the PEG-lipid is 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (poly-ethylene glycol)-2000] or 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000.

### Claim 24 (depends on 23)

The nanoparticle composition of claim 23, wherein the nanoparticle composition comprises the PEG-lipid in a range from 0.1 mol % to 10 mol % of the PEG-lipid per nanoparticle composition.

### Claim 25 (depends on 18)

The nanoparticle composition of claim 18, further comprising at least one of a phospholipid and cholesterol or derivative thereof.

### Claim 26 (depends on 25)

The nanoparticle composition of claim 25, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or distearoylphosphatidylcholine (DSPC).

### Claim 27 (depends on 25)

The nanoparticle composition of claim 25, wherein the nanoparticle composition comprises the phospholipid in a range from 10 mol % to 60 mol % of the phospholipid per nanoparticle composition where mol % of phospholipid=(mol of phospholipid/[mol of phospholipid+mol of cholesterol or derivative thereof+mol of PEG lipid+mol of nucleic acid carrier+mol of nucleic acid])×100.

### Claim 28 (depends on 25)

The nanoparticle composition of claim 25, wherein the nanoparticle composition comprises the cholesterol or derivative thereof in a range from 20 mol % to 75 mol % of the cholesterol or derivative thereof per nanoparticle composition where mol % of cholesterol or derivative thereof=(mol of cholesterol or derivative thereof/[mol of cholesterol or derivative thereof+mol of phospholipid+mol of PEG lipid+mol of nucleic acid carrier+mol of nucleic acid])×100.

### Claim 29 (depends on 18)

A method for treating or preventing a disease or condition in a subject comprising: administering a therapeutically effective amount of the nanoparticle composition of claim 18 to a subject.

### Claim 30 (depends on 18)

A method for delivering a nucleic acid to a subject comprising administering the nanoparticle composition of claim 18 to the subject.
